Search Result

Results for "

EGFR+inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (10) AMPK (1) Amyloid-β (2) Anaplastic lymphoma kinase (ALK) (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (74) Atg8/LC3 (1) Autophagy (6) Bcl-2 Family (9) Btk (3) c-Kit (1) c-Met/HGFR (1) CaMK (2) Caspase (8) CDK (2) COX (2) DNA/RNA Synthesis (1) Drug Derivative (4) Drug Intermediate (2) Drug Metabolite (3) EGFR (263) Endogenous Metabolite (5) ERK (10) Estrogen Receptor/ERR (1) Ferroptosis (1) Histone Methyltransferase (1) HSP (1) Interleukin Related (1) Isotope-Labeled Compounds (3) JAK (1) JNK (1) Ligands for Target Protein for PROTAC (1) MCHR1 (GPR24) (1) MDM-2/p53 (3) MEK (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) mTOR (1) Necroptosis (1) NF-κB (1) NO Synthase (1) Orthopoxvirus (4) P-glycoprotein (2) p38 MAPK (4) PARP (1) PD-1/PD-L1 (1) PERK (1) PI3K (3) Progesterone Receptor (1) PROTACs (2) Raf (6) Reactive Oxygen Species (ROS) (1) Reference Standards (22) Ribosomal S6 Kinase (RSK) (1) STAT (3) Survivin (2) TAM Receptor (1) TGF-beta/Smad (1) TrxR (1) VEGFR (8)
By Research Areas:	Cancer (268) Cardiovascular Disease (3) Endocrinology (2) Infection (9) Inflammation/Immunology (10) Metabolic Disease (7) Neurological Disease (6)
Click Chemistry:	Alkynes (8)

275

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15772

Osimertinib Maximum Cited Publications 185 Publications Verification AZD-9291; Mereletinib	EGFR	Cancer
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective *EGFR* inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-14596

Genistein Maximum Cited Publications 88 Publications Verification NPI 031L	EGFR Autophagy Apoptosis Endogenous Metabolite	Cancer
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., *EGFR*) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-32721

Neratinib 20+ Cited Publications HKI-272	EGFR	Cancer
Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and *EGFR* inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-15772A

Osimertinib mesylate Maximum Cited Publications 185 Publications Verification AZD-9291 mesylate; Mereletinib mesylate	EGFR	Cancer
Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective *EGFR* inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-32721B

Neratinib maleate 20+ Cited Publications HKI-272 maleate	EGFR	Cancer
Neratinib (HKI-272) maleate is an orally available, irreversible, highly selective HER2 and *EGFR* inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-15772R

Osimertinib (Standard) AZD-9291 (Standard); Mereletinib (Standard)	Reference Standards EGFR	Cancer
Osimertinib (Standard) is the analytical standard of Osimertinib. This product is intended for research and analytical applications. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective *EGFR* inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-13050

Sapitinib 15+ Cited Publications AZD-8931	EGFR	Cancer
Sapitinib (AZD-8931) is a reversible, ATP competitive *EGFR* inhibitor of with IC₅₀s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.

HY-15644

Tyrphostin 23 5+ Cited Publications Tyrphostin A23; RG-50810; AG 18	EGFR	Cancer
Tyrphostin 23 (Tyrphostin A23) is an *EGFR* inhibitor with an IC₅₀ and K_iof 35 and 11 μM, respectively.

HY-18957

Lifirafenib 2 Publications Verification BGB-283	EGFR Raf	Cancer
Lifirafenib (BGB-283) is a novel and potent Raf Kinase and *EGFR* inhibitor with IC₅₀ values of 23 and 29 nM for recombinant BRaf ^V600E and EGFR, respectively.

HY-14346

PD153035 5+ Cited Publications SU-5271; AG1517; ZM 252868	EGFR	Cancer
PD153035 (SU-5271; AG1517; ZM 252868) is a potent *EGFR* inhibitor with K_i and IC₅₀ of 6 and 25 pM, respectively.

HY-19729

Naquotinib 5 Publications Verification ASP8273	EGFR	Cancer
Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible *EGFR* inhibitor; with IC₅₀s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.

HY-78869

*Mutated EGFR-IN-1* 1 Publications Verification Osimertinib analog	Drug Derivative	Infection Metabolic Disease Cancer
Mutated EGFR-IN-1 (Osimertinib analog) (Intermediate 168) is a structural analog of Osimertinib (HY-15772) and can be used as a pharmaceutical intermediate for EGFR inhibitors .

HY-12872

Nazartinib 5+ Cited Publications EGF816	EGFR	Cancer
Nazartinib (EGF816) is a covalent mutant-selective *EGFR* inhibitor, with K_i and K_inact of 31 nM and 0.222 min ⁻¹ on EGFR(L858R/790M) mutant, respectively.

HY-10367A

Canertinib dihydrochloride 5+ Cited Publications CI-1033 dihydrochloride; PD-183805 dihydrochloride	EGFR Orthopoxvirus	Infection Cancer
Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible *EGFR* inhibitor; inhibits cellular *EGFR* and ErbB2 autophosphorylation with IC₅₀s of 7.4 and 9 nM. Canertinib dihydrochloride is active against vaccinia virus respiratory infection in mice .

HY-13895

WHI-P154 1 Publications Verification	EGFR JAK Apoptosis	Cancer
WHI-P154 is a potent *EGFR* inhibitor, and also modestly blocks JAK3, with IC₅₀s of 4 nM and 1.8 μM, respectively.

HY-10530

Varlitinib 2 Publications Verification ASLAN001; ARRY-334543	EGFR	Cancer
Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR* inhibitor* with IC₅₀s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively .

HY-13897

CNX-2006	EGFR	Cancer
CNX-2006 is a mutant-selective and irreversible *EGFR* inhibitor with an IC₅₀ below 20 nM for EGFR ^T790M.

HY-15772S

Osimertinib-d6 AZD-9291-d₆; Mereletinib-d₆	EGFR	Cancer
Osimertinib-d₆ is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-19803

Naquotinib mesylate 5 Publications Verification ASP8273 mesylate	EGFR	Cancer
Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible *EGFR* inhibitor; with IC₅₀s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.

HY-13984

NT-1 1 Publications Verification EGFR mutant-IN-3	EGFR ERK Apoptosis Drug Derivative	Cancer
NT-1 (EGFR mutant-IN-3) is a potent mutant *EGFR* inhibitor and an analog of Osimertinib (HY-15772). This mutant EGFR inhibitor suppresses FGFR ^WT with an IC₅₀ of 0.4 nM. NT-1 also inhibits EGFR ^L858R, EGFR ^{Exon 19 deletion} and EGFR ^T790M. NT-1 exerts deeper inhibition on *p-EGFR* and p-ERK, and induces tumor cell apoptosis. NT-1 can be used in colorectal cancer research .

HY-B1394

Khellin 2 Publications Verification	EGFR	Cardiovascular Disease Cancer
Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an *EGFR* inhibitor with an IC₅₀ of 0.15 µM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects .

HY-13785

ZM 306416 2 Publications Verification CB 676475	VEGFR	Cancer
ZM-306416 (CB 676475) is a potent inhibitor of VEGFR with IC₅₀s of 0.1 and 2 μM for KDR and Flt, respectively. ZM-306416 is also a *EGFR* inhibitor with an IC₅₀ of <10 nM.

HY-101426

RG14620 1 Publications Verification Tyrphostin RG14620	EGFR	Cancer
RG14620 is an *EGFR* inhibitor with an IC₅₀ of 3 μM.

HY-100962

(E)-AG 99 1 Publications Verification (E)-Tyrphostin 46; (E)-Tyrphostin AG 99	EGFR	Cancer
(E)-AG 99 ((E)-Tyrphostin 46) is a potent *EGFR* inhibitor .

HY-12013

PD153035 Hydrochloride 5+ Cited Publications SU-5271 Hydrochloride; AG1517 Hydrochloride; ZM 252868 Hydrochloride	EGFR	Cancer
PD153035 Hydrochloride (SU-5271 Hydrochloride) is a potent *EGFR* inhibitor with K_i and IC₅₀ of 6 and 25 pM, respectively.

HY-138627A

AST5902 trimesylate	EGFR Drug Metabolite	Cancer
AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an *EGFR* inhibitor .

HY-135805B

(Rac)-JBJ-04-125-02 acetate	EGFR	Cancer
(Rac)-JBJ-04-125-02 acetate is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, selective mutagenesis, allosteric and orally active EGFR inhibitor .

HY-153974

BBT-176	EGFR	Cancer
BBT-176 is an orally effective *EGFR* inhibitor. BBT-176 has inhibitory activity against multiple EGFR C797S mutant cell lines. BBT-176 is commonly used in cancer research .

HY-149530

EGFR-IN-86	EGFR Apoptosis	Cancer
EGFR-IN-86 (compound 4i) is an EGFR inhibitor (IC₅₀: 1.5 nM) with high activity against glioblastoma. EGFR-IN-86 induces apoptosis and arrests the U87 cell cycle in the G2/M phase .

HY-15772AR

Osimertinib mesylate (Standard) AZD-9291 mesylate (Standard); Mereletinib mesylate (Standard)	Reference Standards EGFR	Cancer
Osimertinib (mesylate) (Standard) is the analytical standard of Osimertinib (mesylate). This product is intended for research and analytical applications. Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective *EGFR* inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-135805A

(Rac)-JBJ-04-125-02	EGFR	Cancer
(Rac)-JBJ-04-125-02 is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active *EGFR* inhibitor .

HY-158149

T-1-PMPA	EGFR Apoptosis	Cancer
T-1-PMPA is a potent *EGFR* inhibitor with apoptotic properties. T-1-PMPA effectively inhibits EGFR ^WT and EGFR ^790m, with IC₅₀ values of 86 nM and 561.73 nM, respectively .

HY-32721R

Neratinib (Standard) HKI-272 (Standard)	Reference Standards EGFR	Cancer
Neratinib (Standard) is the analytical standard of Neratinib. This product is intended for research and analytical applications. Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and *EGFR* inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-P99921

Enapotamab vedotin HuMax-AXL-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) .

HY-101041

(E)-AG 556 (E)-Tyrphostin AG 556	EGFR	Inflammation/Immunology
(E)-AG 556 is a highly selective *EGFR* inhibitor and also blocks LPS-induced TNF-α production .

HY-162890

EGFR-IN-122	EGFR	Cancer
EGFR-IN-122 (compound Yfq07) is a potent *EGFR* inhibitor. EGFR-IN-122 suppresses the proliferation of PC-9GR and HCC827GR cells .

HY-135914

JBJ-02-112-05	EGFR	Cancer
JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active *EGFR* inhibitor with an IC₅₀ of 15 nM for EGFR ^L858R/T790M .

HY-100520

EGFR-IN-2	EGFR	Cancer
EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation *EGFR* inhibitor.

HY-12872B

Nazartinib S-enantiomer EGF816 (S-enantiomer)	EGFR	Others
Nazartinib S-enantiomer (EGF816 S-enantiomer) is the less active S-enantiomer of Nazartinib. Nazartinib (EGF816) is an *EGFR* inhibitor.

HY-174293

Osimertinib dimer	Drug Derivative	Cancer
Osimertinib dimer is a dimer of Osimertinib (HY-15772). Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective *EGFR* inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-138746

EGFR-IN-15	EGFR	Cancer
EGFR-IN-15 (compound I-005) is a *EGFR* inhibitor with an IC₅₀ of 4 nM. EGFR-IN-15 can be used for oncological diseases research .

HY-146262

LDC0496	EGFR	Cancer
LDC0496 is a potent and selective *EGFR* inhibitor. LDC0496 possesses intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations, as well as selectivity over wild type EGFR and within the kinome .

HY-145823

EGFR-IN-42	EGFR	Cancer
EGFR-IN-42 (Compound 17b) is a potent inhibitor of *EGFR* with single-digit nanomolar activity. EGFR-IN-42 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-42 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-42 has superior anti-cancer activity .

HY-145824

EGFR-IN-43	EGFR	Cancer
EGFR-IN-43 (Compound 17c) is a potent inhibitor of *EGFR* with single-digit nanomolar activity. EGFR-IN-43 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-43 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-43 has superior anti-cancer activity .

HY-153744

JGK-068S	EGFR	Cancer
JGK-068S (compound I) is a potent *EGFR* inhibitor .

HY-103437

EGFR-IN-80	EGFR	Cancer
EGFR-IN-80 (compound 30) is an *EGFR* inhibitor with a pIC₅₀ of 10.6 .

HY-163354

EGFR-IN-103	EGFR	Cancer
EGFR-IN-103 (compound 1) is a potent *EGFR* inhibitor with an IC₅₀ of 6 nM for pEGFR .

HY-169570

EGFR-IN-149	EGFR	Cancer
EGFR-IN-149 (Compound 3-OH) is an *EGFR* inhibitor (IC₅₀: 0.42 nM) .

HY-142681

EGFR-IN-28	EGFR	Cancer
EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .

HY-169346

Pred17	EGFR	Cancer
Pred17 is a potent *EGFR* inhibitor. Pred17 has the potential for the research of lung cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990957

Ficerafusp alfa BCA-101; FMAB2	EGFR TGF-beta/Smad	Inflammation/Immunology Cancer
Ficerafusp alfa (BCA-101) is a bispecific antibody targeting *EGFR* and TGFβ, with a K_d of 2.58 nM against *EGFR* and a K_d of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against *EGFR*-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .

HY-P99041A

*Panitumumab (anti-EGFR)*	EGFR	Cancer
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .

HY-P99921

Enapotamab vedotin HuMax-AXL-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14596

Genistein Maximum Cited Publications 88 Publications Verification NPI 031L	Classification of Application Fields Anti-aging Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Leguminosae Glycine max (L.) merr Sunscreen Phenols Polyphenols Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones Source Classification Cancer	EGFR Autophagy Apoptosis Endogenous Metabolite
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., *EGFR*) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-N1988

Cucurbitacin IIa 1 Publications Verification Hemslecin A	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl. Disease Research Fields Source Classification Cancer	Survivin Apoptosis EGFR Caspase p38 MAPK Autophagy MEK Raf ERK STAT CaMK
Cucurbitacin IIa (Hemslecin A) is an orally active, blood-brain barrier-permeable *EGFR* inhibitor with an IC₅₀ of 1.455 nM against human EGFR. Cucurbitacin IIa induces caspase-3-dependent apoptosis, downregulates survivin expression, enhances autophagy levels, disrupts the actin cytoskeleton via actin aggregation, arrests the cell cycle at the G2/M phase, and exerts anti-inflammatory activity by inhibiting the *EGFR-MAPK* signaling pathway. Cucurbitacin IIa can be used in the research of inflammation-related diseases, depression, and cancers such as non-small cell lung cancer .

HY-N0211

Cyasterone 2 Publications Verification	Classification of Application Fields Crotalaria sessiliflora L. Labiatae Amaranthaceae Plants Disease Research Fields Achyranthes bidentata Steroids Cancer Source Classification	EGFR Apoptosis
Cyasterone, a natural *EGFR* inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors .

HY-14596R

Genistein (Standard) Maximum Cited Publications 88 Publications Verification NPI 031L (Standard)	Classification of Application Fields Anti-aging Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Leguminosae Glycine max (L.) merr Sunscreen Phenols Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Source Classification Cancer	Reference Standards EGFR Autophagy Apoptosis Endogenous Metabolite
Genistein (Standard) is the analytical standard of Genistein. This product is intended for research and analytical applications. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., *EGFR*) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-B1394

Khellin 2 Publications Verification	Cardiovascular Disease Classification of Application Fields Artemisia cana Pursh Lignans Phenylpropanoids Umbelliferae Plants Disease Research Fields Source Classification	EGFR
Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an *EGFR* inhibitor with an IC₅₀ of 0.15 µM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects .

HY-B1394R

Khellin (Standard)	Structural Classification Artemisia cana Pursh Lignans Phenylpropanoids Umbelliferae Plants Source Classification	Reference Standards EGFR
Khellin (Standard) is the analytical standard of Khellin. This product is intended for research and analytical applications. Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an EGFR inhibitor with an IC50 of 0.15 μM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects .

HY-N0211R

Cyasterone (Standard)	Structural Classification Crotalaria sessiliflora L. Labiatae Amaranthaceae Plants Achyranthes bidentata Steroids Source Classification	Reference Standards EGFR Apoptosis
Cyasterone (Standard) is the analytical standard of Cyasterone. This product is intended for research and analytical applications. Cyasterone, a natural EGFR inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors .

HY-N1988R

Cucurbitacin IIa (Standard) Hemslecin A (Standard)	Triterpenes Structural Classification Terpenoids Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl. Source Classification	Reference Standards Apoptosis EGFR Autophagy MEK Caspase ERK STAT Survivin Raf p38 MAPK CaMK
Cucurbitacin IIa (Hemslecin A) (Standard) is the analytical standard for Cucurbitacin IIa (HY-N1988). This product is used for research and analytical applications. Cucurbitacin IIa is an orally active, blood-brain barrier-penetrating *EGFR* inhibitor with an IC₅₀ of 1.455 nM for human EGFR. Cucurbitacin IIa induces caspase-3 dependent cell apoptosis, downregulates survivin expression, enhances autophagy levels, disrupts the actin cytoskeleton through actin aggregation, blocks the cell cycle at the G2/M phase, and inhibits the *EGFR-MAPK* signaling pathway to exert anti-inflammatory activity. Cucurbitacin IIa can be used in research on inflammatory-related diseases, depression, and non-small cell lung cancer and other cancers.

HY-165394

Melafolone	Structural Classification Natural Products Polygonaceae Adiantum venustum Don Plants Source Classification	COX EGFR PD-1/PD-L1 PI3K Akt
Melafolone is a potent dual *COX-2/EGFR* inhibitor with IC₅₀s of 13.2 μM (COX-2) and 17.4 μM (EGFR). Melafolone enhances the effect of anti-PD-1 through vascular normalization and PD-L1 downregulation via the PI3K/Akt pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone can be used for lung cancer research .

Cat. No.	Product Name	Chemical Structure

HY-14596S

Genistein-d4
Genistein-d₄ is the deuterium labeled Genistein. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis .

HY-15772S1

Osimertinib-13C,d3
Osimertinib- ¹³C,d₃ is the deuterium and ¹³C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.

HY-15772S

Osimertinib-d6
Osimertinib-d₆ is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-142283AS

Dosimertinib-d5 mesylate
Dosimertinib-d₅ (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d₅ (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₅ (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d₅ (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC) .

HY-142283

Dosimertinib
Dosimertinib-d₃-d₃ is a potent and orally active EGFR inhibitor. Dosimertinib-d₃-d₃ decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₃-d₃ shows antiproliferative and anti-tumor activity. Dosimertinib-d₃-d₃ has the potential for the research of non-small-cell lung cancer (NSCLC) .

HY-B0793S1

AZ-5104-d2
AZ-5104-d₂ is the deuterium labeled AZ-5104. AZ-5104 is an EGFR inhibitor with IC₅₀s of 1 nM, 6 nM, 1 nM, 25 nM and 7 nM for EGFRL858R/T790M, EGFRL858R, EGFRL861Q, EGFR and ErbB4, respectively .

HY-15164AS

Icotinib-d4

Icotinib-d₄ is the deuterium-labeled Icotinib (HY-15164A). Icotinib-d₄ (BPI-2009) is a potent and specific EGFR inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib-d₄ is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-112870AS

Firmonertinib-d3 mesylate

Firmonertinib-d₃ (Alflutinib-d₃) mesylate is the deuterium labeled Firmonertinib mesylate (HY-112870A). Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.

Cat. No.	Product Name		Classification

HY-15164A

Icotinib 5+ Cited Publications BPI-2009		Alkynes
Icotinib (BPI-2009) is a potent, CNS-penetrant and specific *EGFR* inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15164

Icotinib Hydrochloride 5+ Cited Publications BPI-2009H		Alkynes
Icotinib Hydrochloride (BPI-2009) is a potent, CNS-penetrant and specific *EGFR* inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-104066

Theliatinib Xiliertinib; HMPL-309		Alkynes
Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective *EGFR* inhibitor with a K_i of 0.05 nM and an IC₅₀ of 3 nM. Theliatinib has an IC₅₀ of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for *EGFR* than other kinases . Theliatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150781

EGFR-IN-71		Alkynes
EGFR-IN-71 is a potent narrow spectrum epidermal growth factor receptor (EGFR) inhibitor with IC₅₀ values of 3.7 μM. EGFR-IN-71 can be used for researching chordoma . EGFR-IN-71 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150782

UNC-CA359		Alkynes
UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC₅₀ value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-104066A

Theliatinib tartrate Xiliertinib tartrate; HMPL-309 tartrate		Alkynes
Theliatinib (Xiliertinib) tartrate is a potent, ATP-competitive, orally active and highly selective *EGFR* inhibitor with a K_i of 0.05 nM and an IC₅₀ of 3 nM. Theliatinib has an IC₅₀ of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for *EGFR* than other kinases . Theliatinib (tartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-164694

Emupertinib TAS3351		Alkynes
Emupertinib (example 37) is a potent *EGFR* inhibitor with IC₅₀ values of <0.3 nM, 0.52 nM, 0.5 nM, 0.69 nM and 0.92 nM for EGFR (d746-750/T790M/C779S), EGFR (L858R/T790M/C797S), EGFR (d746-750/C797S), EGFR (L858R/C797S), and EGFR (wild-type), respectively .

HY-181701

EGFR-IN-202		Alkynes
EGFR-IN-202 is an epidermal growth factor receptor (EGFR) inhibitor that selectively targets EGFR exon 20 insertion mutations. EGFR-IN-202 can be used in research related to non-small cell lung cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks